Significant Weight Loss With Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Is Associated With Significant Reductions in Use of Concomitant Medications For Cardiometabolic Diseases Over 108 Weeks

被引：0

作者：

Garvey, W. Timothy

Najarian, Thomas

Peterson, Craig A.

机构：

来源：

OBESITY | 2011年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S176 / S176

页数：1

共 31 条

[21] WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE
Davidson, Michael
Bowden, Charles H.
Day, Wesley W.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E545 - E545
[22] A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A101 - A101
[23] Weight Loss (WL) With Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Correlates With Improvements in Liver Function in Overweight/Obese Adults With Elevated Alanine Aminotransferase (ALT)
Klein, Samuel
Najarian, Thomas
Troupin, Barbara
Day, Wesley W.
OBESITY, 2011, 19 : S177 - S177
[24] Low-Dose, Controlled-Release Phentermine/Topiramate (PHEM/TPM CR) Reduces Adiposity, Improves Cardiometabolic Risk in Overweight/Obese Patients
Gallagher, Dympna
Punyanitya, Mark
Bowden, Charles
Peterson, Craig
OBESITY, 2010, 18 : S154 - S154
[25] Long-term weight loss with controlled-release phentermine/topiramate reverses metabolic syndrome and improves associated traits
Toplak, H.
Rossner, S.
Garvey, W. T.
Troupin, B.
Bowden, C. H.
DIABETOLOGIA, 2011, 54 : S370 - S370
[26] Changes in Glycemic Parameters and Antidiabetic Medication Use by Degree of Weight Loss (WL) With Lifestyle Modification and Phentermine/Topiramate Extended-Release (PHEN/TPM ER)
Kushner, Robert
Troupin, Barbara
DIABETES, 2013, 62 : A544 - A545
[27] EFFECT OF WEIGHT LOSS (WL) ON CONCOMITANT MEDICATION COSTS IN OBESE/OVERWEIGHT INDIVIDUALS WITH METABOLIC SYNDROME (METS) RECEIVING PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)
Kahan, S.
Karnawat, S.
VALUE IN HEALTH, 2015, 18 (03) : A297 - A297
[28] Effects of Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus (T2DM)
Ryan, Donna H.
Gadde, Kishore
Wilson, Leland F.
Troupin, Barbara
DIABETES, 2010, 59 : A491 - A491
[29] Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities.
Garvey, W. T.
Bowden, C. H.
Day, W. W.
ENDOCRINE REVIEWS, 2010, 31 (03)
[30] EFFECTS OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) TREATMENT ON WEIGHT LOSS (WL) WHEN STRATIFIED BY BASELINE BODY MASS INDEX (BMI) OVER 1 YEAR
Ryan, D.
Church, T.
Karnawat, S.
Troupin, B.
VALUE IN HEALTH, 2013, 16 (03) : A112 - A112

← 1 2 3 4 →